(EQWL) Invesco S&P 100 Equal Weight - Ratings and Ratios
Large-Cap Equities, S&P 100, Equal Weight, U.S
Dividends
| Dividend Yield | 1.65% |
| Yield on Cost 5y | 3.19% |
| Yield CAGR 5y | 8.37% |
| Payout Consistency | 95.5% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 11.7% |
| Value at Risk 5%th | 19.8% |
| Relative Tail Risk | 2.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | -1.70 |
| CAGR/Max DD | 1.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.316 |
| Beta | 0.780 |
| Beta Downside | 0.851 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.95% |
| Mean DD | 2.19% |
| Median DD | 1.45% |
Description: EQWL Invesco S&P 100 Equal Weight November 12, 2025
The Invesco S&P 100 Equal Weight ETF (NYSE ARCA: EQWL) is designed to track an equal-weighted version of the S&P 100® Index, allocating at least 90 % of its assets to the index’s constituents. By weighting each of the 100 large-cap U.S. stocks equally, the fund reduces concentration risk relative to market-cap-weighted peers and offers a diversified exposure to the “large-value” segment.
Key metrics as of the latest filing: the fund carries an expense ratio of roughly 0.20 % and manages about $2-3 billion in assets, with an average daily trading volume exceeding 500,000 shares, which supports liquidity. Because the index is equal-weighted, sectors such as technology, health-care, and consumer discretionary-each representing roughly 15-20 % of holdings-tend to have a larger impact on performance than in cap-weighted versions. Recent macro drivers include U.S. consumer-spending trends and the Federal Reserve’s policy stance, both of which influence earnings across the diversified S&P 100 constituents.
If you want a deeper, data-driven view of EQWL’s risk-return profile and how it fits into a broader portfolio, ValueRay’s analytics platform offers granular, up-to-date charts and scenario analyses worth exploring.
What is the price of EQWL shares?
Over the past week, the price has changed by +2.70%, over one month by -0.17%, over three months by +4.06% and over the past year by +10.96%.
Is EQWL a buy, sell or hold?
What are the forecasts/targets for the EQWL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 133.9 | 14.1% |
EQWL Fundamental Data Overview November 19, 2025
Beta = 0.95
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.84b USD (1.84b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.84b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.84b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.89% (E(1.84b)/V(1.84b) * Re(8.89%) + (debt-free company))
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for EQWL ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle